Pub Date : 2025-09-10DOI: 10.1016/j.canrad.2025.104719
Anna Gueiderikh , Morgan Michalet , Catherine Dejean , Ulrike Schick , Catherine Durdux , Alain Fourquet , Youlia Kirova
We present the updated recommendations of the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology) on radiotherapy and pregnancy. The occurrence of cancer during pregnancy is a rare event (approximately 1 in 1000 pregnancies). The risks for the embryo or the foetus depend on the gestational age at the time of irradiation. The main risks are malformations with microcephaly and mental retardation. There is also a risk of radiation-induced cancer in the unborn child. In the case of only supradiaphragmatic irradiation, radiotherapy can be performed most often in pregnant women without risk to the foetus. On the other hand, in the case of an indication for subdiaphragmatic irradiation, therapeutic termination of the pregnancy should be proposed. In all cases, when radiotherapy is chosen, a phantom estimation of the dose delivered to the foetus, confirmed by in vivo measurement, is recommended. Conformational radiotherapy is the preferred technique because of the lower dose delivered to the foetus (except for tumour locations where other techniques such as intensity-modulated radiotherapy are recommended).
{"title":"Radiotherapy and pregnancy: 2025 update","authors":"Anna Gueiderikh , Morgan Michalet , Catherine Dejean , Ulrike Schick , Catherine Durdux , Alain Fourquet , Youlia Kirova","doi":"10.1016/j.canrad.2025.104719","DOIUrl":"10.1016/j.canrad.2025.104719","url":null,"abstract":"<div><div>We present the updated recommendations of the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology) on radiotherapy and pregnancy. The occurrence of cancer during pregnancy is a rare event (approximately 1 in 1000 pregnancies). The risks for the embryo or the foetus depend on the gestational age at the time of irradiation. The main risks are malformations with microcephaly and mental retardation. There is also a risk of radiation-induced cancer in the unborn child. In the case of only supradiaphragmatic irradiation, radiotherapy can be performed most often in pregnant women without risk to the foetus. On the other hand, in the case of an indication for subdiaphragmatic irradiation, therapeutic termination of the pregnancy should be proposed. In all cases, when radiotherapy is chosen, a phantom estimation of the dose delivered to the foetus, confirmed by in vivo measurement, is recommended. Conformational radiotherapy is the preferred technique because of the lower dose delivered to the foetus (except for tumour locations where other techniques such as intensity-modulated radiotherapy are recommended).</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104719"},"PeriodicalIF":1.4,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145027041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-10DOI: 10.1016/j.canrad.2025.104714
Jean-Michel Hannoun-Lévi , Sophie Renard , Pascal Pommier , Lucie Houdou , Fabien Mignot , Julien Charret , Pierre Blanchard , Cyrus Chargari , Marjorie Ferré
The RecoRad™ 2025 recommendations for best practice in brachytherapy procedures are updated based on the 2022 article. This new brachytherapy article took into account recent data published in the literature as well as international recommendations. The different brachytherapy steps are successively described from the treatment preparation (brachytherapy technique prescription; procedure and applicators, dedicated images for planification, dose distribution analysis and validation) to the end of the procedure as well as post-treatment surveillance.
{"title":"Best practice in brachytherapy: 2025 update","authors":"Jean-Michel Hannoun-Lévi , Sophie Renard , Pascal Pommier , Lucie Houdou , Fabien Mignot , Julien Charret , Pierre Blanchard , Cyrus Chargari , Marjorie Ferré","doi":"10.1016/j.canrad.2025.104714","DOIUrl":"10.1016/j.canrad.2025.104714","url":null,"abstract":"<div><div>The RecoRad™ 2025 recommendations for best practice in brachytherapy procedures are updated based on the 2022 article. This new brachytherapy article took into account recent data published in the literature as well as international recommendations. The different brachytherapy steps are successively described from the treatment preparation (brachytherapy technique prescription; procedure and applicators, dedicated images for planification, dose distribution analysis and validation) to the end of the procedure as well as post-treatment surveillance.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104714"},"PeriodicalIF":1.4,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145027043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-10DOI: 10.1016/j.canrad.2025.104712
Charles Raynaud , Stéphane Supiot , Jennifer Le Guévelou , Pierre Blanchard , Jihane Boustani , Maximilien Rogé , Guilhem Roubaud , Vincent Marchesi , Igor Latorzeff , Paul Sargos
This article aims to report the recommendations from the French society for radiation oncology (Société française de radiothérapie oncologique, SFRO) on the use of external beam radiotherapy in the management of testicular cancer. Testicular cancers account for 1 % of adult neoplasms yet represent the most frequently diagnosed urological tumour in young men. Most of testicular cancers (95 %) are germ cell tumours, which include both seminomatous and non-seminomatous tumours. Surveillance is the preferred option for stage I seminoma following orchidectomy, but adjuvant chemotherapy or para-aortic radiotherapy remain possible options. For stages IIA/IIB seminoma, either chemotherapy or para-aortic and ipsilateral iliac nodal areas irradiation can be proposed. In non-seminomatous tumours, chemotherapy is the standard treatment. Target volumes, doses, fractionation regimens, and considerations for organs at risk are discussed. Follow-up recommendations are provided, aiming to ensure both early detection of cancer recurrence and late treatment-related side effects. These guidelines highlight the importance of a multidisciplinary approach for the management of germ cell tumours as well as careful consideration of long-term toxicities, in this young patient population with a long-life expectancy.
本文旨在报道法国放射肿瘤学学会（societacranaise de radithacrirapie oncologique， SFRO）关于使用外束放疗治疗睾丸癌的建议。睾丸癌占成人肿瘤的1%，但却是年轻男性中最常诊断的泌尿系统肿瘤。大多数睾丸癌（95%）是生殖细胞肿瘤，包括半细胞瘤和非半细胞瘤肿瘤。监测是睾丸切除术后I期精原细胞瘤的首选，但辅助化疗或主动脉旁放疗仍然是可能的选择。对于IIA/IIB期精原细胞瘤，可以建议化疗或主动脉旁和同侧髂淋巴结照射。对于非半瘤性肿瘤，化疗是标准的治疗方法。靶体积，剂量，分离方案，并考虑器官的危险进行了讨论。提供随访建议，旨在确保早期发现癌症复发和晚期治疗相关副作用。这些指南强调了多学科方法对生殖细胞肿瘤管理的重要性，以及对这一预期寿命较长的年轻患者群体长期毒性的仔细考虑。
{"title":"Role of radiotherapy in the management of testicular cancer: Recommendations from the French society for radiation oncology","authors":"Charles Raynaud , Stéphane Supiot , Jennifer Le Guévelou , Pierre Blanchard , Jihane Boustani , Maximilien Rogé , Guilhem Roubaud , Vincent Marchesi , Igor Latorzeff , Paul Sargos","doi":"10.1016/j.canrad.2025.104712","DOIUrl":"10.1016/j.canrad.2025.104712","url":null,"abstract":"<div><div>This article aims to report the recommendations from the French society for radiation oncology (Société française de radiothérapie oncologique, SFRO) on the use of external beam radiotherapy in the management of testicular cancer. Testicular cancers account for 1 % of adult neoplasms yet represent the most frequently diagnosed urological tumour in young men. Most of testicular cancers (95 %) are germ cell tumours, which include both seminomatous and non-seminomatous tumours. Surveillance is the preferred option for stage I seminoma following orchidectomy, but adjuvant chemotherapy or para-aortic radiotherapy remain possible options. For stages IIA/IIB seminoma, either chemotherapy or para-aortic and ipsilateral iliac nodal areas irradiation can be proposed. In non-seminomatous tumours, chemotherapy is the standard treatment. Target volumes, doses, fractionation regimens, and considerations for organs at risk are discussed. Follow-up recommendations are provided, aiming to ensure both early detection of cancer recurrence and late treatment-related side effects. These guidelines highlight the importance of a multidisciplinary approach for the management of germ cell tumours as well as careful consideration of long-term toxicities, in this young patient population with a long-life expectancy.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104712"},"PeriodicalIF":1.4,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145027040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-06DOI: 10.1016/j.canrad.2025.104718
Igor Latorzeff , Alizée Camps-Malea , Véronique Vendrely , David Azria , Laure Parent , Émilie Bayart , Stéphane Supiot
The purpose of the first three editions of the guidelines for external radiotherapy procedures (RecoRad™, published in 2008, 2016 and 2021 respectively), was to issue recommendations aimed at optimising, harmonising and standardising practices. The purpose of this fourth edition, follow the same plan and takes into account recent technological improvements along with findings from literature. Part one describes the daily use of general principles; part two describes every step of the process treatment for the main types of cancer. This new edition is also an opportunity to integrate new chapters.
{"title":"Guidelines for external radiotherapy and brachytherapy procedures: 4th edition","authors":"Igor Latorzeff , Alizée Camps-Malea , Véronique Vendrely , David Azria , Laure Parent , Émilie Bayart , Stéphane Supiot","doi":"10.1016/j.canrad.2025.104718","DOIUrl":"10.1016/j.canrad.2025.104718","url":null,"abstract":"<div><div>The purpose of the first three editions of the guidelines for external radiotherapy procedures (RecoRad™, published in 2008, 2016 and 2021 respectively), was to issue recommendations aimed at optimising, harmonising and standardising practices. The purpose of this fourth edition, follow the same plan and takes into account recent technological improvements along with findings from literature. Part one describes the daily use of general principles; part two describes every step of the process treatment for the main types of cancer. This new edition is also an opportunity to integrate new chapters.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104718"},"PeriodicalIF":1.4,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145004515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Since 2007, therapeutic patient education has been recognized as essential in complementing medical care, particularly for chronic diseases like prostate cancer. To address its underdevelopment in oncology, we have developed a therapeutic patient education programme at our institution specifically for patients with prostate cancer. The aim of this article is to describe the process of developing and implementing this programme and to present a first evaluation at 2 years.
Material and methods
This study describes the development of a therapeutic patient education programme for patients with prostate cancer at our institution, detailing the steps taken – including needs assessment, staff training, programme declaration, and structuring of educational stages – followed by a comprehensive evaluation of its implementation. The 2-year assessment analysed patient registries, questionnaires, and educator feedback to evaluate the program's effectiveness and impact on patient care.
Results
The development of our therapeutic patient education programme for patients with prostate cancer, which involved assessing patient needs, training multidisciplinary staff, designing targeted workshops, and obtaining authorization from the French regional health agency. Over 24 months, the programme successfully engaged 249 patients in five different workshops, with high satisfaction rates, fostered team collaboration, and highlighted challenges such as logistical constraints and patient participation barriers.
Conclusion
Although our therapeutic education programme showed high patient satisfaction and exceeded enrolment expectations, future steps include expanding programme visibility, developing digital options, addressing geographic barriers, and conducting controlled studies to evaluate its impact on self-efficacy and symptom management. Therapeutic patient education in oncology addresses the complex needs of patients with chronic prostate cancer by improving quality of life through multidisciplinary collaboration and dedicated efforts, while also enhancing team cohesion.
{"title":"Therapeutic education for patients with prostate cancer: Feasibility, implementation, and preliminary outcomes","authors":"Thérèse Valy-Foti , Elvire Martin-Mervoyer , Josselin Sebille , Sophie Allain , Stéphane Supiot , Virginie Berger , Valentine Guimas","doi":"10.1016/j.canrad.2025.104708","DOIUrl":"10.1016/j.canrad.2025.104708","url":null,"abstract":"<div><h3>Purpose</h3><div>Since 2007, therapeutic patient education has been recognized as essential in complementing medical care, particularly for chronic diseases like prostate cancer. To address its underdevelopment in oncology, we have developed a therapeutic patient education programme at our institution specifically for patients with prostate cancer. The aim of this article is to describe the process of developing and implementing this programme and to present a first evaluation at 2 years.</div></div><div><h3>Material and methods</h3><div>This study describes the development of a therapeutic patient education programme for patients with prostate cancer at our institution, detailing the steps taken – including needs assessment, staff training, programme declaration, and structuring of educational stages – followed by a comprehensive evaluation of its implementation. The 2-year assessment analysed patient registries, questionnaires, and educator feedback to evaluate the program's effectiveness and impact on patient care.</div></div><div><h3>Results</h3><div>The development of our therapeutic patient education programme for patients with prostate cancer, which involved assessing patient needs, training multidisciplinary staff, designing targeted workshops, and obtaining authorization from the French regional health agency. Over 24 months, the programme successfully engaged 249 patients in five different workshops, with high satisfaction rates, fostered team collaboration, and highlighted challenges such as logistical constraints and patient participation barriers.</div></div><div><h3>Conclusion</h3><div>Although our therapeutic education programme showed high patient satisfaction and exceeded enrolment expectations, future steps include expanding programme visibility, developing digital options, addressing geographic barriers, and conducting controlled studies to evaluate its impact on self-efficacy and symptom management. Therapeutic patient education in oncology addresses the complex needs of patients with chronic prostate cancer by improving quality of life through multidisciplinary collaboration and dedicated efforts, while also enhancing team cohesion.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 5","pages":"Article 104708"},"PeriodicalIF":1.4,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144885584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-21DOI: 10.1016/j.canrad.2025.104711
Rafik Nebbache , Julian Biau , Florence Huguet , Séverine Racadot , Mailys de Meric de Bellefon , Laure Vieillevigne , Yoann Pointreau , Pierre Blanchard
Nasopharyngeal cancers are rare in France but much more common in endemic regions such as Southeast Asia, North Africa, and Alaska. Radiotherapy remains the cornerstone of treatment, combined with chemotherapy for locally advanced cases. The technical aspects of radiotherapy are complex due to the proximity of numerous critical structures. Recent studies have explored the benefits of combining systemic therapies, such as immunotherapy, with radiotherapy, the advantage of de-escalating irradiated lymph node volumes to reduce toxicity while maintaining therapeutic efficacy, and the value of monitoring via Epstein-Barr virus circulating tumour DNA to improve patient follow-up. Here, we present the updated recommendations of the French society of radiation oncology (Société française de radiothérapie oncologique, SFRO) concerning the indications and technical modalities of radiotherapy in nasopharyngeal cancers.
鼻咽癌在法国很少见，但在东南亚、北非和阿拉斯加等流行地区更为常见。放疗仍然是治疗的基础，局部晚期病例联合化疗。由于邻近许多关键结构，放射治疗的技术方面很复杂。最近的研究探索了全身治疗（如免疫治疗）与放疗相结合的益处，降低照射淋巴结体积以降低毒性同时保持治疗效果的优势，以及通过Epstein-Barr病毒循环肿瘤DNA监测以改善患者随访的价值。在这里，我们提出了法国放射肿瘤学学会（societsfranaise de radiothacrirapie oncologique， SFRO）关于鼻咽癌放射治疗的适应症和技术模式的最新建议。
{"title":"Radiotherapy for nasopharyngeal cancer: 2025 update","authors":"Rafik Nebbache , Julian Biau , Florence Huguet , Séverine Racadot , Mailys de Meric de Bellefon , Laure Vieillevigne , Yoann Pointreau , Pierre Blanchard","doi":"10.1016/j.canrad.2025.104711","DOIUrl":"10.1016/j.canrad.2025.104711","url":null,"abstract":"<div><div>Nasopharyngeal cancers are rare in France but much more common in endemic regions such as Southeast Asia, North Africa, and Alaska. Radiotherapy remains the cornerstone of treatment, combined with chemotherapy for locally advanced cases. The technical aspects of radiotherapy are complex due to the proximity of numerous critical structures. Recent studies have explored the benefits of combining systemic therapies, such as immunotherapy, with radiotherapy, the advantage of de-escalating irradiated lymph node volumes to reduce toxicity while maintaining therapeutic efficacy, and the value of monitoring via Epstein-Barr virus circulating tumour DNA to improve patient follow-up. Here, we present the updated recommendations of the French society of radiation oncology (Société française de radiothérapie oncologique, SFRO) concerning the indications and technical modalities of radiotherapy in nasopharyngeal cancers.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104711"},"PeriodicalIF":1.4,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144880051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-20DOI: 10.1016/j.canrad.2025.104710
Delphine Antoni , Ulrike Schick , Delphine Jarnet , Stéphanie Josset , Jocelyne Mazurier , Laure Parent , David Pasquier , Thomas Lacornerie
Stereotactic body radiotherapy, also referred to extreme hypofractionation, uses advanced delivery techniques to administer high radiation doses per fraction. Stereotactic body radiotherapy has led to a real revolution for the treatment in localized non-small cell lung cancer. Recognized as the standard treatment for inoperable early-stage non-small cell lung cancer, there is an increasing use of stereotactic body radiotherapy in complex situations related to patient or tumour characteristics. The aim of this review was to report the current evidence so far, and to assess specificities of this irradiation technique, especially in terms of dose prescription modalities.
{"title":"Stereotactic radiotherapy for lung cancer: Influence of prescription modality on clinical outcome","authors":"Delphine Antoni , Ulrike Schick , Delphine Jarnet , Stéphanie Josset , Jocelyne Mazurier , Laure Parent , David Pasquier , Thomas Lacornerie","doi":"10.1016/j.canrad.2025.104710","DOIUrl":"10.1016/j.canrad.2025.104710","url":null,"abstract":"<div><div>Stereotactic body radiotherapy, also referred to extreme hypofractionation, uses advanced delivery techniques to administer high radiation doses per fraction. Stereotactic body radiotherapy has led to a real revolution for the treatment in localized non-small cell lung cancer. Recognized as the standard treatment for inoperable early-stage non-small cell lung cancer, there is an increasing use of stereotactic body radiotherapy in complex situations related to patient or tumour characteristics. The aim of this review was to report the current evidence so far, and to assess specificities of this irradiation technique, especially in terms of dose prescription modalities.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 5","pages":"Article 104710"},"PeriodicalIF":1.4,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144879323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-20DOI: 10.1016/j.canrad.2025.104716
Maxime Bertrand-Chevrier , Olivier Riou , Alexandre Orthuon , Igor Bessières , Nicolas Jaksic , Valentine Guimas , Véronique Vendrely , Florence Huguet
We present the updated recommendations of the French Society of Radiotherapy Oncology (Société française de radiothérapie oncologique, SFRO) on radiotherapy for pancreatic cancer. The place of radiation therapy in the treatment of patients with resectable or locally advanced pancreatic cancer is still controversial. In the postoperative setting, the standard treatment is adjuvant chemotherapy with 5-fluorouracil, irinotecan and oxaliplatin (“folfirinox” regimen) for 6 months. Adjuvant chemoradiotherapy may be beneficial for patients with N0 cancer. After induction chemotherapy, neoadjuvant chemoradiotherapy is used for borderline tumours in order to increase the chances of complete resection (R0) even if its benefit on patient survival has not been demonstrated. For locally advanced tumours, induction chemotherapy followed in non-progressive patients by chemoradiotherapy increases local control and the chances of resectability. Intensity-modulated radiotherapy reduces the doses received by organs at risk. Tumour movements related to breathing must be taken into account. Stereotaxic radiotherapy increases the dose received by the tumour while protecting neighbouring healthy organs.
我们提出了法国放射肿瘤学学会（societsfranaise de radiothacrirapie oncologique， SFRO）关于胰腺癌放射治疗的最新建议。放射治疗在可切除或局部晚期胰腺癌患者的治疗中的地位仍然存在争议。术后标准治疗为5-氟尿嘧啶、伊立替康和奥沙利铂辅助化疗（folfirinox方案）6个月。辅助放化疗可能对无癌患者有益。诱导化疗后，新辅助放化疗用于边缘性肿瘤，以增加完全切除（R0）的机会，即使其对患者生存的益处尚未得到证实。对于局部晚期肿瘤，诱导化疗后，非进展患者的放化疗增加了局部控制和可切除的机会。调强放疗可减少危险器官接受的剂量。与呼吸有关的肿瘤运动必须考虑在内。立体定向放射治疗增加肿瘤接受的剂量，同时保护邻近的健康器官。
{"title":"Radiotherapy of pancreatic cancers: 2025 update","authors":"Maxime Bertrand-Chevrier , Olivier Riou , Alexandre Orthuon , Igor Bessières , Nicolas Jaksic , Valentine Guimas , Véronique Vendrely , Florence Huguet","doi":"10.1016/j.canrad.2025.104716","DOIUrl":"10.1016/j.canrad.2025.104716","url":null,"abstract":"<div><div>We present the updated recommendations of the French Society of Radiotherapy Oncology (Société française de radiothérapie oncologique, SFRO) on radiotherapy for pancreatic cancer. The place of radiation therapy in the treatment of patients with resectable or locally advanced pancreatic cancer is still controversial. In the postoperative setting, the standard treatment is adjuvant chemotherapy with 5-fluorouracil, irinotecan and oxaliplatin (“folfirinox” regimen) for 6 months. Adjuvant chemoradiotherapy may be beneficial for patients with N0 cancer. After induction chemotherapy, neoadjuvant chemoradiotherapy is used for borderline tumours in order to increase the chances of complete resection (R0) even if its benefit on patient survival has not been demonstrated. For locally advanced tumours, induction chemotherapy followed in non-progressive patients by chemoradiotherapy increases local control and the chances of resectability. Intensity-modulated radiotherapy reduces the doses received by organs at risk. Tumour movements related to breathing must be taken into account. Stereotaxic radiotherapy increases the dose received by the tumour while protecting neighbouring healthy organs.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104716"},"PeriodicalIF":1.4,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144880050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-20DOI: 10.1016/j.canrad.2025.104709
Ulrike Schick , Delphine Antoni , Stéphanie Josset , Thomas Lacornerie , Jocelyne Mazurier , Laure Parent , David Pasquier
Stereotactic body radiotherapy, also referred to as extreme hypofractionation, uses advanced delivery techniques to administer high radiation doses per fraction. Since its introduction in the early 2000s, several single-centre and two multi-institutional randomized trials have evaluated stereotactic body radiotherapy for prostate cancer, typically reporting median follow-ups of 5 to 10 years. Given favourable outcomes, stereotactic body radiotherapy has now become a standard of care for intermediate prostate cancer. The aim of this review is to report the current evidence so far, and to assess specificities of this irradiation modality. Extreme fractionation in case of pelvic irradiation or intraprostatic relapse will not be addressed in this review.
{"title":"Stereotactic radiotherapy for prostate cancer","authors":"Ulrike Schick , Delphine Antoni , Stéphanie Josset , Thomas Lacornerie , Jocelyne Mazurier , Laure Parent , David Pasquier","doi":"10.1016/j.canrad.2025.104709","DOIUrl":"10.1016/j.canrad.2025.104709","url":null,"abstract":"<div><div>Stereotactic body radiotherapy, also referred to as extreme hypofractionation, uses advanced delivery techniques to administer high radiation doses per fraction. Since its introduction in the early 2000s, several single-centre and two multi-institutional randomized trials have evaluated stereotactic body radiotherapy for prostate cancer, typically reporting median follow-ups of 5 to 10 years. Given favourable outcomes, stereotactic body radiotherapy has now become a standard of care for intermediate prostate cancer. The aim of this review is to report the current evidence so far, and to assess specificities of this irradiation modality. Extreme fractionation in case of pelvic irradiation or intraprostatic relapse will not be addressed in this review.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 5","pages":"Article 104709"},"PeriodicalIF":1.4,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144879779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-20DOI: 10.1016/j.canrad.2025.104715
Paul Sargos , Louis-Marie Sauvage , Jonathan Khalifa , Olivier Riou , David Azria , Geneviève Loos , Christophe Hennequin , Vincent Marchesi , Igor Latorzeff , Stéphane Supiot
We present the recommendations of the Société française de radiothérapie oncologie (SFRO; the French society for radiation oncology) regarding the indications and techniques for external beam radiotherapy for bladder cancer. Together with radical cystectomy, trimodal therapy for well-selected patients is one of the standard-of-care treatments in the management of localized muscle invasive bladder cancer, defined as a maximal trans-urethral resection of the bladder tumour, followed by radiotherapy and concomitant chemotherapy. Adjuvant radiotherapy is an option for patients with pathological high-risk bladder cancer. In the metastatic setting, consolidative radiotherapy is still under evaluation. Palliative radiotherapy using a hypofractionated regimen is a valid option in symptomatic patients.
{"title":"Role of radiotherapy in the management of bladder cancer: Recommendations of the French Society for Radiation Oncology, 2025 update","authors":"Paul Sargos , Louis-Marie Sauvage , Jonathan Khalifa , Olivier Riou , David Azria , Geneviève Loos , Christophe Hennequin , Vincent Marchesi , Igor Latorzeff , Stéphane Supiot","doi":"10.1016/j.canrad.2025.104715","DOIUrl":"10.1016/j.canrad.2025.104715","url":null,"abstract":"<div><div>We present the recommendations of the Société française de radiothérapie oncologie (SFRO; the French society for radiation oncology) regarding the indications and techniques for external beam radiotherapy for bladder cancer. Together with radical cystectomy, trimodal therapy for well-selected patients is one of the standard-of-care treatments in the management of localized muscle invasive bladder cancer, defined as a maximal trans-urethral resection of the bladder tumour, followed by radiotherapy and concomitant chemotherapy. Adjuvant radiotherapy is an option for patients with pathological high-risk bladder cancer. In the metastatic setting, consolidative radiotherapy is still under evaluation. Palliative radiotherapy using a hypofractionated regimen is a valid option in symptomatic patients.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104715"},"PeriodicalIF":1.4,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144880049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号